Growth-Promoting Role of the miR-106a∼363 Cluster in Ewing Sarcoma

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Dylla, Layne ^a   Jedlicka, Paul ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 106A; MICRORNA 106B; MICRORNA 15A; MICRORNA 17; MICRORNA 25; MICRORNA 92A; MICRORNA 93; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL SPECIFICITY; CLONOGENESIS; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; EWING SARCOMA; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC PROCEDURES; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MICRORNA INHIBITION; MICRORNA SPONGE BLOCKADE; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PHENOTYPE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; MICRORNAS; SARCOMA, EWING; UP-REGULATION;

EID: 84876856161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063032     Document Type: Article

References (59)

1. Riggi N, Suva ML, Stamenkovic I, (2009) Ewing's sarcoma origin: from duel to duality. Expert Rev Anticancer Ther 9: 1025-1030.
2. Arvand A, Denny CT, (2001) Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20: 5747-5754.
3. Toomey EC, Schiffman JD, Lessnick SL, (2010) Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 29: 4504-4516.
4. McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, et al. (2011) A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene 30: 4910-4920.
5. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, et al. (2011) Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma. Oncogene 30: 2173-2180.
6. Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, et al. (2012) MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene.
7. De Vito C, Riggi N, Cornaz S, Suva ML, Baumer K, et al. (2012) A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell 21: 807-821.
8. De Vito C, Riggi N, Suva ML, Janiszewska M, Horlbeck J, et al. (2011) Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS One 6: e23592.
9. Esiashvili N, Goodman M, Marcus RB Jr, (2008) Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol 30: 425-430.
10. Ludwig JA, (2008) Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 20: 412-418.
11. Subbiah V, Anderson P, (2011) Targeted Therapy of Ewing's Sarcoma. Sarcoma 2011: 686985.
12. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, et al. (2011) R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 6: e26060.
13. Borinstein SC, Barkauskas DA, Krailo M, Scher D, Scher L, et al. (2011) Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group. Cancer 117: 4966-4976.
14. Frieden M, Orum H, (2008) Locked nucleic acid holds promise in the treatment of cancer. Curr Pharm Des 14: 1138-1142.
15. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, et al. (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478: 404-407.
16. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, et al. (2011) Efficient in vivo microRNA targeting of liver metastasis. Oncogene 30: 1481-1488.
17. Fabian MR, Sonenberg N, Filipowicz W, (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
18. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z, (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15: 1443-1461.
19. Olive V, Jiang I, He L, (2010) mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42: 1348-1354.
20. Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, et al. (2007) Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 26: 6099-6105.
21. Landais S, Landry S, Legault P, Rassart E, (2007) Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67: 5699-5707.
22. Wang Z, Liu M, Zhu H, Zhang W, He S, et al. (2012) miR-106a Is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog.
23. Thapa DR, Li X, Jamieson BD, Martinez-Maza O, (2011) Overexpression of microRNAs from the miR-17-92 paralog clusters in AIDS-related non-Hodgkin's lymphomas. PLoS One 6: e20781.
24. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, et al. (2011) Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res 17: 1463-1473.
25. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, et al. (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
26. Petrocca F, Vecchione A, Croce CM, (2008) Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 68: 8191-8194.
27. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, et al. (2010) Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3: ra29.
28. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, et al. (2012) miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226: 796-805.
29. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, et al. (2010) The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 70: 8233-8246.
30. Fu X, Tian J, Zhang L, Chen Y, Hao Q, (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586: 1279-1286.
31. Jiang Y, Wu Y, Greenlee AR, Wu J, Han Z, et al. (2011) miR-106a-mediated malignant transformation of cells induced by anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide. Toxicol Sci 119: 50-60.
32. Kan T, Sato F, Ito T, Matsumura N, David S, et al. (2009) The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 136: 1689-1700.
33. Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, et al. (2009) The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 23: 3957-3966.
34. Nittner D, Lambertz I, Clermont F, Mestdagh P, Kohler C, et al. (2012) Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol 14: 958-965.
35. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT, (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
36. Mu P, Han YC, Betel D, Yao E, Squatrito M, et al. (2009) Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806-2811.
37. Ebert MS, Neilson JR, Sharp PA, (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721-726.
38. Dai L, Wang W, Zhang S, Jiang Q, Wang R, et al. (2012) Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo. Cell Biol Int 36: 765-770.
39. Diniz MG, Gomes CC, de Castro WH, Guimaraes AL, De Paula AM, et al. (2012) miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. Cell Oncol (Dordr) 35: 285-291.
40. Klein U, Lia M, Crespo M, Siegel R, Shen Q, et al. (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-40.
41. Ofir M, Hacohen D, Ginsberg D, (2011) MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res. 9: 440-447.
42. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, et al. (2012) Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family. Cancer Res 72: 5945-5955.
43. Lindow M, Kauppinen S, (2012) Discovering the first microRNA-targeted drug. J Cell Biol 199: 407-412.
44. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, et al. (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886.
45. Gonzalez I, Vicent S, de Alava E, Lecanda F, (2007) EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med (Berl) 85: 1015-1029.
46. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, et al. (1998) EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16: 1248-1255.
47. Bandres E, Malumbres R, Escalada A, Cubedo E, Gonzalez I, et al. (2005) Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type. J Pediatr Hematol Oncol 27: 537-542.
48. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, et al. (2010) Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 28: 1989-1994.
49. Liu Q, Fu H, Sun F, Zhang H, Tie Y, et al. (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36: 5391-5404.
50. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, et al. (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
51. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, Ginel-Picardo A, Smith PG, et al. (2012) WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene.
52. Bueno MJ, Gomez de Cedron M, Laresgoiti U, Fernandez-Piqueras J, Zubiaga AM, et al. (2010) Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Mol Cell Biol 30: 2983-2995.
53. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, et al. (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272-286.
54. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, et al. (2012) Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119: 1162-1172.
55. Pickering BF, Yu D, Van Dyke MW, (2011) Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. J Biol Chem 286: 44095-44103.
56. Tang R, Li L, Zhu D, Hou D, Cao T, et al. (2012) Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res 22: 504-515.
57. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, et al. (2011) Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One 6: e23205.
58. Ebert MS, Sharp PA, (2010) MicroRNA sponges: progress and possibilities. RNA 16: 2043-2050.
59. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.